{"groups":[{"description":"Patients administered 40 mg of basiliximab as a single intravenous dose on day +7, +8, or +9 following infusion of allogeneic peripheral blood hematopoietic cells","id":"FG000","title":"Overall"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This protocol has 17 patients. The study was stopped prior to 20 due to the meeting of a stopping rule of 5 or more deaths within the first 15 patients. An additional patient was enrolled after the stopping rule was met. This patient was followed for safety/AE but is not included in the analysis of the efficacy measures, as recommended by the IRB."}